Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eli Lilly
(NY:
LLY
)
952.74
-1.43 (-0.15%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
August 20, 2024
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates,
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
MarketBeat Week in Review – 8/5 - 8/9
August 10, 2024
Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Novo Nordisk's Shares Go on a Rollercoaster Ride After Earnings
August 09, 2024
Novo Nordisk fell over 8% after its earnings release but recovered nearly all of those losses the next day. It needs to increase supplies of semaglutide.
Via
MarketBeat
Topics
ETFs
It's Too Soon to Buy the Dip in Weight Loss Drugmakers
August 09, 2024
Obesity drugs are a hot market and one still accelerating as new treatments are approved and usage widens. The bad news is that much of the growth is priced in.
Via
MarketBeat
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
August 07, 2024
Via
Investor Brand Network
Amgen's MariTide Weight Loss Potential: Stock Outlook
August 07, 2024
Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials.
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
August 06, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:PFE),(NYSE:LLY),(NYSE:GSK),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
July 25, 2024
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
July 25, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Positive News is Driving This Cancer Drug Maker’s Stock Higher
July 15, 2024
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather
Via
MarketBeat
MarketBeat Week in Review – 7/8 - 7/12
July 13, 2024
Stocks took investors on quite a ride this week, with the S&P 500 hitting a new record high, then falling back on Thursday before rallying to end the week
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Eli Lilly Finalizes Acquisition Agreement to Acquire Morphic for $3.2 Billion – InsideArbitrage
July 09, 2024
Via
AB Newswire
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
July 09, 2024
Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been
Via
MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Morphic Holding, Inc. (Nasdaq - MORF), Desktop Metal, Inc. (NYSE - DM), Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR)
July 08, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
First Choice Neurology Pioneering Neurologists Administer the New FDA-Approved Drug Kisunla
July 11, 2024
JUPITER, Fla. - July 11, 2024 - PRLog -- First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum...
Via
PRLog
Exposures
Product Safety
MarketBeat Week in Review – 7/1 - 7/5
July 06, 2024
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
July 03, 2024
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases
Via
MarketBeat
Exposures
Product Safety
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
July 02, 2024
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy
Via
MarketBeat
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
July 01, 2024
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound.
Via
MarketBeat
Exposures
Product Safety
The Top 3 Sectors Poised For Growth This Summer
June 24, 2024
Communications, technology, and healthcare are the three hottest sectors for growth, but not all stocks will rise with the tides.
Via
MarketBeat
Topics
ETFs
MarketBeat Week in Review – 6/17 - 6/21
June 22, 2024
Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Eli Lilly's Stock Surge Driven by GLP-1 Demand
June 20, 2024
Shares of Eli Lilly stock are about to hit a new all-time high, sponsored by the pending approval of new weight loss drugs
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche
June 19, 2024
The race to develop effective Alzheimer's treatments presents significant opportunities and inherent risks for healthcare investors.
Via
MarketBeat
Exposures
Product Safety
3 Strong Buy Stocks for a Sizzling Summer Rally
June 18, 2024
Investors can take a deep breath before the next earnings season, but they should still invest in equities, including these three gems hiding in plain sight
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
June 03, 2024
Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments
Via
MarketBeat
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
June 11, 2024
EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
4 Stocks Making New Highs Despite Market Weakness
June 03, 2024
While the market faced challenges on Friday, Birkenstock, NetApp, Eli Lilly, and Aflac showed notable strength by achieving new 52-week highs.
Via
MarketBeat
LifeMD Can Surge on Its GLP-1 Offerings
May 28, 2024
LifeMD is a leading telehealth provider that investors should take note of; the company is entering the GLP-1 market, and its stock could soar as a result
Via
MarketBeat
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
June 11, 2024
From
FN Media Group LLC
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.